Bio­haven’s $230M of­fer­ing; Plus, three new PIPEs

Read on for news about Ben­itec Bio­phar­ma, Ko­r­ro Bio, Zu­ra Bio, Oc­u­lar Ther­a­peu­tix and SK bio­phar­ma­ceu­ti­cals:

Bio­haven to seek $230M pub­lic of­fer­ing: The com­pa­ny’s of­fer­ing fol­lows an up­date to its BHV-1300 pro­gram, an IgG pro­tein de­grad­er be­ing de­vel­oped for au­toim­mune con­di­tions, in an SEC fil­ing this week. Bio­haven is ex­pect­ed to share more da­ta from a Phase 1 healthy vol­un­teer tri­al at its R&D Day on May 29. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER